Vivus | search
Click here to view Vivus news from 60+ newspapers.
Bookmark or Share- VIVUS: Advancing Innovative Clinical TherapiesImproving patient quality of life. With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases.
- VIVUS | VIVUS Contact Directory - AmericasAmericas — contact information by country. For general questions about VIVUS or for media inquiries, please contact us using the information provided below. Please note, we cannot respond to questions about general medical information or questions regarding your personal medical condition.
- FDA Approves QSYMIA® for the Treatment of Obesity in ... - Vivus LLCJul 20, 2022. CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adolescents (12-17 years old) with an initial body-mass index (BMI) in the 95th percentile ...
- VIVUS Announces it will Provide Telehealth to Patients through an ...VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs.
- VIVUS | Our HistoryLearn about the evolution of VIVUS and the expansion of our business globally. Swipe, click through or select a year to navigate our interactive timeline. VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases.
More
